Join Us! hVIVO’s Dr Anthony Gilbert speaking at 4th ISIRV-AVG Conference

May 15, 2015 9:42 am

Dr Anthony Gilbert, hVIVO (formerly Retroscreen Virology) Medical Director, will be speaking at the 4th ISIRV-AVG conference in early June in Austin, Texas, USA.

The event is organised by the International Society for Influenza and other Respiratory Viral Diseases – Anti Viral Group (ISIRV-AVG), and takes place at the University of Texas at Austin USA, 4-6 June 2015.

The conference, titled “Novel Antiviral Therapies for Influenza and other Respiratory Viruses: Bench to Bedside” is expected to attract around 200 delegates who will focus on the pre-clinical and clinical development of novel antivirals and therapeutics against influenza and other respiratory viruses, from discovery to licensure. The overall objective is to bring together those working in these areas to review current activity and progress.

Dr Gilbert will be presenting within the “Regulatory Issues & Clinical Trial Endpoints” session and his presentation, which will give insight into the pioneering work conducted by hVIVO, is entitled “The Human Viral Challenge Model – Accelerating Drug and Vaccine Development”.

There is a great unmet need for antiviral therapies for common and novel respiratory viral infections, so the three days is going to be exceptionally insightful to explore how to address this area and accelerate delivery.

Dr Gilbert commented: “As well as the need to improve the therapeutic development approach to fight influenza, there is an urgent need to also develop novel therapies for other respiratory diseases such as RSV and HRV. I am looking forward to participating in a lively conference, and to contributing by presenting some of our own hVIVO breakthrough insights into disease understanding through the pioneering use of the human challenge model.”

Find out more about the ISIRV-AVG conference (and to register to attend the event) here:

If you would like to connect with Dr. Anthony Gilbert or one of our Business Development representatives during or after ISIRV, please contact us using the below form.

Comments are closed here.